Corporate governance can be biotech's Achilles' heel
11 February, 2005 by Melissa TrudingerSome Australian biotechs are getting creative with company structure. But analysts prefer their companies to play it straight.
Takeda buys US drug-developer Syrxx
11 February, 2005 by Renate KrelleJapanese pharmaceutical giant Takeda has paid US$270 million in cash to acquire Syrxx, a private drug-development company based in San Diego.
Tissue therapies posts small loss
10 February, 2005 by Renate KrelleTissue Therapies Limited (ASX:TIS) has released its half-year results, recording a net loss of $445,400, in line with budget expectations.
Board briefs: Neuren; Peptech; Cytopia
10 February, 2005 by Renate KrelleExecutives with US experience and contacts in the international equities market remain as popular as ever amongst Australian biotechs, if this week's board appointments are anything to go by.
Acrux gets results in libido trial
10 February, 2005 by Melissa TrudingerAcrux (ASX: ACR) has reported positive results from the Phase IIb trial of its testosterone MDTS spray in pre-menopausal women with low libido.
Chemgenex acquires platinum drug
09 February, 2005 by Melissa TrudingerChemgenex Pharmaceuticals (ASX: CXS) has acquired a novel anti-cancer drug from the University of Texas MD Anderson Cancer Center.
Peplin maintains clinical trial ambitions
09 February, 2005 by Renate KrellePeplin Biotech's (ASX:PEP) half-year results have revealed a AUD$13 million cash balance -- enough, the company says, to complete three Phase II clinical trials of its skin cancer treatment PEP005.
AustCancer cheered by survival study
09 February, 2005 by Renate KrelleAustralian Cancer Technology has reaped quick rewards and impressed shareholders with a drug it licensed in September last year, which has doubled the survival rate of patient with pancreatic cancer in a Phase I/II study conducted in Germany.
Solbec completes Phase I psoriasis trial
09 February, 2005 by Melissa TrudingerSolbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
FDA gives Ventracor trial conditional approval
08 February, 2005 by Melissa TrudingerVentracor (ASX: VCR) has received conditional approval from the US FDA for a feasibility study leading up to a full scale trial of its cardiac assist device as a bridge-to-transplant.
Chemgenex drug shows stamina
08 February, 2005 by Melissa TrudingerChemgenex (ASX: CXS) has provided updated results from its Phase I /II clinical study of anti-cancer drug Quinamed at the American Association for Cancer Research's Oncogenomics 2005 conference in the US.
Sassine leaves Visiomed
07 February, 2005 by Renate KrelleWA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Peptech reaffirms acquisition strategy
07 February, 2005 by Renate KrellePeptech (ASX:PTD) CEO Mel Bridges used today's annual general meeting to reveal that the company is keen to use its AUD$65 million warchest to fund acquisitions.
In brief: ResMed, Meditech, Ventracor
04 February, 2005 by Staff WritersResMed (ASX:RMD) shares were up almost 5 per cent today after the company announced record revenue and income results for the quarter ended December 31 Revenue for the quarter was US$103.9 million, a 26 per cent increase over the same quarter last year. Net income for the quarter was US$17.4 million.
Biotech's in for a good year, says Burrill
04 February, 2005 by Renate KrelleThe Burrill Biotech Select Index slipped 4.6 per cent in January, but Steve Burrill is bullish about 2005, despite the ramifications of the Merck-Vioxx situation spilling over into the biotech sector.
